Watch More Highlights

Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Simmons Cancer Center, discusses phase III findings that showed metformin, which has been linked to beneficial anticancer effects in some research, did not improve invasive disease–free survival or other outcomes in patients with estrogen or progesterone receptor–positive or –negative breast cancer. The study authors concluded that this agent should not be used as adjuvant treatment (Abstract GS1-08).

Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.